A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis

Antoine Leuzy, Tharick A. Pascoal, Olof Strandberg, Philip Insel, Ruben Smith, Niklas Mattsson-Carlgren, Andréa L. Benedet, Hannah Cho, Chul H. Lyoo, Renaud La Joie, Gil D. Rabinovici, Rik Ossenkoppele, Pedro Rosa-Neto, Oskar Hansson

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


Purpose: This study aims to determine whether comparable target regions of interest (ROIs) and cut-offs can be used across [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau positron emission tomography (PET) tracers for differential diagnosis of Alzheimer’s disease (AD) dementia vs either cognitively unimpaired (CU) individuals or non-AD neurodegenerative diseases. Methods: A total of 1755 participants underwent tau PET using either [18F]flortaucipir (n = 975), [18F]RO948 (n = 493), or [18F]MK6240 (n = 287). SUVR values were calculated across four theory-driven ROIs and several tracer-specific data-driven (hierarchical clustering) regions of interest (ROIs). Diagnostic performance and cut-offs for ROIs were determined using receiver operating characteristic analyses and the Youden index, respectively. Results: Comparable diagnostic performance (area under the receiver operating characteristic curve [AUC]) was observed between theory- and data-driven ROIs. The theory-defined temporal meta-ROI generally performed very well for all three tracers (AUCs: 0.926–0.996). An SUVR value of approximately 1.35 was a common threshold when using this ROI. Conclusion: The temporal meta-ROI can be used for differential diagnosis of dementia patients with [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET with high accuracy, and that using very similar cut-offs of around 1.35 SUVR. This ROI/SUVR cut-off can also be applied across tracers to define tau positivity.

Original languageEnglish
Pages (from-to)2295-2305
Number of pages11
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Issue number7
Publication statusPublished - 2021 Jul

Bibliographical note

Funding Information:
Dr. Hansson reported receiving grants from Roche during the conduct of the study as well as grants from Roche, non-financial support from GE Healthcare, and grants from Biogen outside the submitted work. AL, TP, OS, PI, RS, NMC, ALB, HC, CHL, RLJ, GR, RO, and PRN report no conflicts of interest.

Funding Information:
Open access funding provided by Lund University. Work at the authors’ research center was supported by the European Research Council, the Swedish Research Council, the Knut and Alice Wallenberg Foundation, the Marianne and Marcus Wallenberg Foundation, the Strategic Research Area MultiPark (Multidisciplinary research in Parkinson disease) at Lund University, the Swedish Alzheimer Foundation, the Swedish Brain Foundation, the Parkinson Foundation of Sweden, the Parkinson Research Foundation, the Skåne University Hospital Foundation, the Bundy Academy, and the Swedish federal government under the Agreement for Medical Education and Research.

Publisher Copyright:
© 2021, The Author(s).

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis'. Together they form a unique fingerprint.

Cite this